secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oric Pharmaceuticals, Inc. (ORIC)
CIK:        0001796280
Form:       8-K
Filed at:   2025-05-05T23:59:59+00:00
Accession:  0000950170-25-063540
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ORIC Q1 cash $224M; extends runway to 2027; plans Phase 3 for 2 programs in 2026
--------------------------------------------------------------------------------

- Cash and investments $223.8M at March 31, 2025; expected to fund operations into 2027 (vs previous guidance of late 2026).
- R&D expenses $24.6M for Q1 2025, up from $22.0M YoY due to pipeline advancement and higher personnel costs.
- Registrational plan for ORIC-944 in mCRPC: first Phase 3 trial targeted for 1H 2026; ORIC-114 Phase 3 in 1L NSCLC expected later in 2026.
- Entered clinical trial collaboration with Johnson & Johnson for ORIC-114 plus subcutaneous amivantamab in 1L EGFR exon 20 NSCLC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1796280/000095017025063540/0000950170-25-063540-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1796280/000095017025063540/oric-20250505.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-063540

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer